Brokerages Set NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) PT at $36.50

by · The Cerbat Gem

Shares of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP – Get Free Report) have earned an average rating of “Moderate Buy” from the six research firms that are covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and four have given a buy recommendation to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $36.50.

A number of analysts have weighed in on NRXP shares. D. Boral Capital restated a “buy” rating and set a $34.00 target price on shares of NRx Pharmaceuticals in a report on Tuesday, December 2nd. Ascendiant Capital Markets upped their price objective on NRx Pharmaceuticals from $46.00 to $47.00 and gave the stock a “buy” rating in a research note on Thursday, October 30th. HC Wainwright reaffirmed a “buy” rating and set a $40.00 price objective on shares of NRx Pharmaceuticals in a research report on Thursday, October 16th. BTIG Research reiterated a “buy” rating and issued a $25.00 target price on shares of NRx Pharmaceuticals in a report on Wednesday, December 3rd. Finally, Zacks Research raised shares of NRx Pharmaceuticals to a “hold” rating in a research report on Wednesday, September 10th.

Get Our Latest Report on NRXP

Institutional Investors Weigh In On NRx Pharmaceuticals

Institutional investors have recently bought and sold shares of the company. Ethos Financial Group LLC purchased a new position in NRx Pharmaceuticals in the third quarter worth $39,000. One Wealth Management Investment & Advisory Services LLC lifted its holdings in shares of NRx Pharmaceuticals by 86.1% during the 3rd quarter. One Wealth Management Investment & Advisory Services LLC now owns 27,991 shares of the company’s stock valued at $92,000 after purchasing an additional 12,950 shares during the last quarter. Two Sigma Investments LP boosted its position in shares of NRx Pharmaceuticals by 66.4% in the 3rd quarter. Two Sigma Investments LP now owns 52,332 shares of the company’s stock worth $173,000 after purchasing an additional 20,880 shares in the last quarter. Geode Capital Management LLC grew its stake in NRx Pharmaceuticals by 27.9% during the 2nd quarter. Geode Capital Management LLC now owns 172,255 shares of the company’s stock worth $562,000 after buying an additional 37,598 shares during the last quarter. Finally, AdvisorShares Investments LLC grew its stake in NRx Pharmaceuticals by 29.7% during the 3rd quarter. AdvisorShares Investments LLC now owns 342,136 shares of the company’s stock worth $1,129,000 after buying an additional 78,339 shares during the last quarter. 4.27% of the stock is currently owned by institutional investors and hedge funds.

NRx Pharmaceuticals Stock Performance

NASDAQ NRXP opened at $2.21 on Monday. NRx Pharmaceuticals has a one year low of $1.15 and a one year high of $6.01. The company has a market capitalization of $62.10 million, a price-to-earnings ratio of -0.94 and a beta of 1.91. The company’s 50-day simple moving average is $2.76 and its two-hundred day simple moving average is $2.88.

NRx Pharmaceuticals (NASDAQ:NRXP – Get Free Report) last announced its quarterly earnings results on Friday, November 14th. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.07). The firm had revenue of $0.24 million for the quarter, compared to analysts’ expectations of $6.83 million. Equities analysts expect that NRx Pharmaceuticals will post -1.75 earnings per share for the current fiscal year.

NRx Pharmaceuticals Company Profile

(Get Free Report)

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.

See Also